Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARAY Stock Summary
In the News
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Accuray's (ARAY) solid product demand raises optimism about the stock.
Accuray (ARAY) Up 1.6% Since Last Earnings Report: Can It Continue?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
7 Screaming Stock Buys for Under $5
While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can't just run up the gut.
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
Accuray Incorporated (ARAY) Q2 2024 Earnings Call Transcript
Accuray Incorporated (ARAY) Q2 2024 Earnings Call Transcript
Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
ARAY Financial details
ARAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.84 | 4.26 | 4.4 | 4.82 | 4.82 | |
Net income per share | -0.19 | 0.04 | -0.07 | -0.06 | -0.1 | |
Operating cash flow per share | -0.34 | -0.02 | 0.43 | -0.03 | 0.17 | |
Free cash flow per share | -0.39 | -0.06 | 0.4 | -0.08 | 0.03 | |
Cash per share | 0.89 | 1.2 | 1.29 | 1 | 0.96 | |
Book value per share | 0.58 | 0.7 | 0.76 | 0.6 | 0.58 | |
Tangible book value per share | -0.1 | 0.05 | 0.12 | -0.05 | -0.05 | |
Share holders equity per share | 0.58 | 0.7 | 0.76 | 0.6 | 0.58 | |
Interest debt per share | 2.02 | 2.67 | 2.4 | 2.49 | 2.32 | |
Market cap | 338.11M | 182.44M | 407.51M | 174.67M | 359.14M | |
Enterprise value | 421.16M | 296.57M | 490.55M | 299.66M | 474.77M | |
P/E ratio | -20.58 | 47.67 | -64.57 | -32.67 | -38.7 | |
Price to sales ratio | 0.81 | 0.48 | 1.03 | 0.41 | 0.8 | |
POCF ratio | -11.41 | -124.2 | 10.58 | -72.78 | 23.11 | |
PFCF ratio | -9.96 | -35.11 | 11.26 | -24.54 | 125.66 | |
P/B Ratio | 6.78 | 2.91 | 5.92 | 3.28 | 6.69 | |
PTB ratio | 6.78 | 2.91 | 5.92 | 3.28 | 6.69 | |
EV to sales | 1.01 | 0.77 | 1.24 | 0.7 | 1.06 | |
Enterprise value over EBITDA | 722.4 | 24.99 | 22.06 | 36.78 | 199.32 | |
EV to operating cash flow | -14.21 | -201.89 | 12.74 | -124.86 | 30.55 | |
EV to free cash flow | -12.4 | -57.07 | 13.55 | -42.11 | 166.12 | |
Earnings yield | -0.05 | 0.02 | -0.02 | -0.03 | -0.03 | |
Free cash flow yield | -0.1 | -0.03 | 0.09 | -0.04 | 0.01 | |
Debt to equity | 3.21 | 3.53 | 2.9 | 4.02 | 3.82 | |
Debt to assets | 0.36 | 0.45 | 0.42 | 0.45 | 0.43 | |
Net debt to EBITDA | 142.45 | 9.62 | 3.73 | 15.34 | 48.54 | |
Current ratio | 1.79 | 1.96 | 1.83 | 1.68 | 1.7 | |
Interest coverage | -0.66 | 0.24 | 0.94 | 0.32 | 0.22 | |
Income quality | 1.8 | -0.38 | -6.1 | 0.45 | -1.67 | |
Dividend Yield | 0 | 0.01 | 0.01 | 0 | 0 | |
Payout ratio | 0 | 0.59 | -0.48 | -0.05 | -0.02 | |
Sales general and administrative to revenue | 0.12 | 0.11 | 0.11 | 0.1 | 0.11 | |
Research and developement to revenue | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | |
Intangibles to total assets | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | |
Capex to operating cash flow | 0.15 | 2.54 | -0.06 | 1.97 | -0.82 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | |
Capex to depreciation | -0.41 | -0.49 | -0.36 | -0.86 | -2.8 | |
Stock based compensation to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham number | 1.57 | 0.82 | 1.1 | 0.9 | 1.14 | |
ROIC | -0.05 | 0.01 | 0.07 | 0.02 | 0.01 | |
Return on tangible assets | -0.04 | 0.01 | -0.01 | -0.01 | -0.02 | |
Graham Net | -1.93 | -2.06 | -1.86 | -2.12 | -2.24 | |
Working capital | 151.89M | 174.37M | 160.41M | 142.03M | 139.4M | |
Tangible asset value | -8.58M | 4.41M | 10.45M | -4.9M | -4.23M | |
Net current asset value | -44.24M | -70.66M | -58.49M | -68.77M | -87.52M | |
Invested capital | 3.21 | 3.53 | 2.9 | 4.02 | 3.82 | |
Average receivables | 88.94M | 100.74M | 87.48M | 89.9M | 84.61M | |
Average payables | 24.63M | 26.34M | 21.3M | 25.4M | 32.54M | |
Average inventory | 114.68M | 127.67M | 130.23M | 134.09M | 143.7M | |
Days sales outstanding | 97.52 | 85.4 | 78.62 | 80.18 | 60.98 | |
Days payables outstanding | 42.13 | 36.22 | 30.01 | 42.37 | 41.94 | |
Days of inventory on hand | 172.18 | 210.69 | 194.12 | 192.34 | 180.42 | |
Receivables turnover | 3.74 | 4.27 | 4.64 | 4.55 | 5.99 | |
Payables turnover | 8.66 | 10.08 | 12.16 | 8.61 | 8.7 | |
Inventory turnover | 2.12 | 1.73 | 1.88 | 1.9 | 2.02 | |
ROE | -0.33 | 0.06 | -0.09 | -0.1 | -0.17 | |
Capex per share | -0.05 | -0.04 | -0.03 | -0.05 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.22 | 1.24 | 1.23 | 1.08 | 1.1 | |
Net income per share | -0.02 | 0.01 | -0.03 | -0.03 | -0.1 | |
Operating cash flow per share | -0.19 | 0.26 | 0.09 | -0.09 | -0.05 | |
Free cash flow per share | -0.21 | 0.24 | 0.01 | -0.1 | -0.06 | |
Cash per share | 0.72 | 0.93 | 0.93 | 0.8 | 0.74 | |
Book value per share | 0.55 | 0.57 | 0.56 | 0.53 | 0.49 | |
Tangible book value per share | -0.07 | -0.04 | -0.04 | -0.07 | -0.1 | |
Share holders equity per share | 0.55 | 0.57 | 0.56 | 0.53 | 0.49 | |
Interest debt per share | 2.24 | 2.16 | 2.17 | 2.15 | 2.1 | |
Market cap | 195.83M | 283.7M | 371.31M | 262.63M | 276.71M | |
Enterprise value | 335.49M | 399.66M | 486.94M | 390.62M | 406.17M | |
P/E ratio | -26.13 | 118.41 | -36.32 | -22.11 | -7.19 | |
Price to sales ratio | 1.71 | 2.4 | 3.14 | 2.53 | 2.58 | |
POCF ratio | -10.87 | 11.52 | 41.81 | -30.57 | -54.33 | |
PFCF ratio | -10.02 | 12.45 | 438.9 | -27.12 | -43.63 | |
P/B Ratio | 3.78 | 5.19 | 6.92 | 5.16 | 5.81 | |
PTB ratio | 3.78 | 5.19 | 6.92 | 5.16 | 5.81 | |
EV to sales | 2.92 | 3.39 | 4.12 | 3.76 | 3.79 | |
Enterprise value over EBITDA | 124.02 | 172.57 | -1.07K | 95.46 | -135.53 | |
EV to operating cash flow | -18.62 | 16.23 | 54.83 | -45.47 | -79.75 | |
EV to free cash flow | -17.16 | 17.54 | 575.58 | -40.34 | -64.04 | |
Earnings yield | -0.01 | 0 | -0.01 | -0.01 | -0.03 | |
Free cash flow yield | -0.1 | 0.08 | 0 | -0.04 | -0.02 | |
Debt to equity | 4.01 | 3.75 | 3.82 | 4.02 | 4.24 | |
Debt to assets | 0.44 | 0.43 | 0.43 | 0.43 | 0.42 | |
Net debt to EBITDA | 51.63 | 50.07 | -253.03 | 31.28 | -43.2 | |
Current ratio | 1.82 | 1.79 | 1.7 | 1.66 | 1.58 | |
Interest coverage | 0.59 | 1.02 | -0.15 | 0.76 | -1.36 | |
Income quality | 9.61 | 41.11 | -3.47 | 2.89 | 0.53 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.55 | 0 | -0.03 | 0 | 0 | |
Sales general and administrative to revenue | 0.1 | 0.09 | 0.11 | 0.13 | 0.12 | |
Research and developement to revenue | 0.13 | 0.12 | 0.12 | 0.13 | 0.14 | |
Intangibles to total assets | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
Capex to operating cash flow | 0.09 | -0.07 | -0.9 | 0.13 | 0.25 | |
Capex to revenue | -0.01 | -0.02 | -0.07 | -0.01 | -0.01 | |
Capex to depreciation | -1.33 | -1.67 | -7.32 | -0.87 | -0.81 | |
Stock based compensation to revenue | 0.03 | 0.01 | 0.02 | 0.02 | 0.02 | |
Graham number | 0.5 | 0.28 | 0.58 | 0.6 | 1.04 | |
ROIC | 0.01 | 0 | 0 | 0.02 | -0.02 | |
Return on tangible assets | 0 | 0 | -0.01 | -0.01 | -0.02 | |
Graham Net | -2.18 | -2.08 | -2.16 | -2.24 | -2.2 | |
Working capital | 152.23M | 151.09M | 139.4M | 132.7M | 121.86M | |
Tangible asset value | -6.3M | -3.36M | -4.23M | -6.88M | -10.23M | |
Net current asset value | -80.08M | -78.1M | -87.52M | -91.74M | -97.53M | |
Invested capital | 4.01 | 3.75 | 3.82 | 4.02 | 4.24 | |
Average receivables | 83.11M | 83.27M | 76.06M | 76.07M | 81.04M | |
Average payables | 33.4M | 31.25M | 31.19M | 34.31M | 37.03M | |
Average inventory | 154.14M | 153.12M | 147.87M | 147.56M | 152.6M | |
Days sales outstanding | 69.94 | 58.97 | 56.89 | 67.02 | 71.1 | |
Days payables outstanding | 42.45 | 32.5 | 37.67 | 48.74 | 49.43 | |
Days of inventory on hand | 195.14 | 170.81 | 162.05 | 209.6 | 195.84 | |
Receivables turnover | 1.29 | 1.53 | 1.58 | 1.34 | 1.27 | |
Payables turnover | 2.12 | 2.77 | 2.39 | 1.85 | 1.82 | |
Inventory turnover | 0.46 | 0.53 | 0.56 | 0.43 | 0.46 | |
ROE | -0.04 | 0.01 | -0.05 | -0.06 | -0.2 | |
Capex per share | -0.02 | -0.02 | -0.08 | -0.01 | -0.01 |
ARAY Frequently Asked Questions
What is Accuray Incorporated stock symbol ?
Accuray Incorporated is a US stock , located in Sunnyvale of Ca and trading under the symbol ARAY
Is Accuray Incorporated buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $7. The lowest prediction is $7 and the highest is $7
What is ARAY stock prediction ?
What is Accuray Incorporated stock quote today ?
Accuray Incorporated stock price is $2.47 today.
Is Accuray Incorporated stock public?
Yes, Accuray Incorporated is a publicly traded company.